Back to top
more

Integra LifeSciences (IART)

(Delayed Data from NSDQ)

$12.56 USD

12.56
2,274,762

+0.25 (2.03%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $12.56 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kevin Cook headshot

Bull of the Day: Penumbra (PEN)

by Kevin Cook

Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech

    Zacks Equity Research

    Integra Lifesciences Picked for Healogics iSupply Program

    by Zacks Equity Research

    Integra Lifesciences' (IART) selection as a key provider for cellular-based tissue products within Healogics' new iSupply program to boost the top line.

      Zacks Equity Research

      Why Is Integra (IART) Down 2.7% Since Last Earnings Report?

      by Zacks Equity Research

      Integra (IART) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.

        Zacks Equity Research

        Integra LifeSciences Codman Arm Strong, Competition Rife

        by Zacks Equity Research

        Integra LifeSciences' (IART) progress within its channel expansion strategy and Codman integration buoys investors' optimism on the stock.

          Zacks Equity Research

          Integra (IART) Reports In-Line Q2 Earnings, Tapers View

          by Zacks Equity Research

          Integra LifeSciences' (IART) balanced segmental revenue growth in Q2 is encouraging.

            Zacks Equity Research

            Integra LifeSciences Global Prospects Solid, Competition Rife

            by Zacks Equity Research

            Integra LifeSciences (IART) continues to expand overseas.

              Zacks Equity Research

              Here's Why You Should Buy Integra LifeSciences (IART) Stock

              by Zacks Equity Research

              Integra LifeSciences' (IART) key developments on the overseas front buoy optimism on the stock among investors.

                Zacks Equity Research

                Why Is Integra LifeSciences (IART) Up 8.5% Since Its Last Earnings Report?

                by Zacks Equity Research

                Integra LifeSciences (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  Zacks Equity Research

                  Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue?

                  by Zacks Equity Research

                  Ligand Pharmaceuticals Incorporated is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LGND for clues.

                    Zacks Equity Research

                    Integra LifeSciences (IART) Tops on Q1 Earnings, '18 View Up

                    by Zacks Equity Research

                    Integra LifeSciences' (IART) revenue growth was primarily driven by high organic revenues, successful progress with Codman integration and progress with the channel expansion strategy.

                      Zacks Equity Research

                      Why Is Integra LifeSciences (IART) Up 3.6% Since Its Last Earnings Report?

                      by Zacks Equity Research

                      Integra LifeSciences (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                        Zacks Equity Research

                        Integra LifeSciences Banks on CSS Segment, Competition Rife

                        by Zacks Equity Research

                        Integra LifeSciences (IART) rides high on strength in the Codman Specialty Surgical segment.

                          Zacks Equity Research

                          Integra LifeSciences (IART) Beats on Q4 Earnings & Revenues

                          by Zacks Equity Research

                          Integra LifeSciences's (IART) solid Q4 revenue growth was primarily driven by high organic revenues and better-than-expected performance by the recently-acquired businesses.

                            Zacks Equity Research

                            Can Segmental Strength Drive Integra's (IART) Q4 Earnings?

                            by Zacks Equity Research

                            Integra LifeSciences (IART) well poised to gain from strength in Orthopedics and Tissue Technologies in Q4.

                              Zacks Equity Research

                              What's in the Cards for Genomic Health (GHDX) in Q4 Earnings?

                              by Zacks Equity Research

                              Similar to last quarter, Genomic Health (GHDX) is expected to gain from higher total product revenues in Q4.

                                Zacks Equity Research

                                Why Earnings Season Could Be Great for Integra LifeSciences (IART)

                                by Zacks Equity Research

                                Integra LifeSciences (IART) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                                  Zacks Equity Research

                                  Integra LifeSciences Global Prospects Solid, Competition Rife

                                  by Zacks Equity Research

                                  Integra LifeSciences (IART) witnesses strong global sales within specialty surgical driven by strength in door repair and tissue ablation franchises in Asia Pacific and Europe.

                                    Zacks Equity Research

                                    Integra LifeSciences Estimates Strong Revenue Figures for Q4

                                    by Zacks Equity Research

                                    Integra LifeSciences (IART) sees strong organic growth in the company's Specialty Surgical Solutions as well as Orthopedics and Tissue Technologies businesses.

                                      Zacks Equity Research

                                      Integra (IART) Up 1.8% Since Earnings Report: Can It Continue?

                                      by Zacks Equity Research

                                      Integra (IART) reported earnings about 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        Zacks Equity Research

                                        Integra Gains on Global Growth, Hurricanes Hamper Business

                                        by Zacks Equity Research

                                        Integra (IART) launches new regenerative products within its Orthopedics and Tissue Technologies segment. However, hurricanes in Q3 grossly affect the wound care and orthopedic procedures in Florida.

                                          Zacks Equity Research

                                          Integra LifeSciences (IART) Misses on Q3 Earnings & Revenues

                                          by Zacks Equity Research

                                          Integra LifeSciences' (IART) raised full-year 2017 revenue guidance buoys optimism.

                                            Zacks Equity Research

                                            Quest Diagnostics (DGX) Beats Earnings in Q3, Updates View

                                            by Zacks Equity Research

                                            Despite hurricanes related financial impact, Quest Diagnostics (DGX) posted year-over-year growth in Q3 on recent acquisitions, tie-ups and strength in several advanced diagnostic offerings.

                                              Zacks Equity Research

                                              Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed

                                              by Zacks Equity Research

                                              Abbott (ABT) posted promising Q3 results primarily on the back of strong EPD sales and emerging market expansion.

                                                Zacks Equity Research

                                                Here's Why You Should Buy Thermo Fisher Scientific (TMO) Now

                                                by Zacks Equity Research

                                                Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.

                                                  Zacks Equity Research

                                                  Here's Why Investors Should Buy Integra LifeSciences Now

                                                  by Zacks Equity Research

                                                  The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.